8-K: Personalis Reports 15% Revenue Growth for 2024, Exceeds Guidance

Personalis, Inc. announced preliminary full-year 2024 revenue of approximately $84.6 million, a 15% increase year-over-year, exceeding their previous guidance.

Summary

• Personalis reported preliminary full-year 2024 revenue of approximately $84.6 million, a 15% increase compared to $73.5 million in 2023.
• This revenue figure exceeded the company's previous full-year guidance range of $83.0 to $84.0 million.
• Revenue from pharma tests and services, enterprise sales, and other customers grew by 20% to approximately $77.2 million in 2024.
• However, revenue from Natera decreased by 20% to approximately $25.4 million for the full year.
• Revenue from population sequencing for the VA MVP decreased by 21% to approximately $7.4 million in 2024.
• Fourth-quarter revenue was approximately $16.8 million, a 15% decrease compared to $19.7 million in the same quarter of 2023.
• The decrease in fourth-quarter revenue was primarily due to the expected decline in revenue from Natera and the VA MVP.
• The company's cash, cash equivalents, and short-term investments totaled approximately $185.0 million as of December 31, 2024, including a $50 million strategic investment from Merck.
• Personalis delivered 1,441 total molecular tests in the fourth quarter of 2024, a 52% increase compared to the third quarter of 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the strong full-year revenue growth and strategic investments, but tempered by the decrease in fourth-quarter revenue and reliance on a few key customers.

Positives

• Full-year revenue grew by 15% year-over-year, demonstrating strong overall growth.
• The company exceeded its own revenue guidance for the full year.
• Revenue from pharma tests and services, enterprise sales, and other customers showed a significant 20% increase.
• The company secured a $50 million strategic investment from Merck, bolstering its financial position.
• The number of molecular tests delivered increased significantly in the fourth quarter, indicating growing demand.
• The company established a long-term commercial collaboration with Moderna.

Negatives

• Fourth-quarter revenue decreased by 15% compared to the same quarter in the previous year.
• Revenue from Natera decreased by 20% for the full year and 41% in the fourth quarter.
• Revenue from the VA MVP decreased by 21% for the full year.
• The decrease in revenue from Natera and the VA MVP significantly impacted the fourth-quarter results.

Risks

• The company's revenue is subject to fluctuations based on the timing and pace of new orders from customers, including Moderna, Merck, and VA MVP.
• The timing of specimen sample receipts from customers can materially impact revenue quarter-over-quarter and year-over-year.
• The company's ability to demonstrate the attributes, advantages, or clinical validity of the NeXT platform is crucial for future growth.
• The rate of adoption and use of the NeXT platform will impact future revenue.
• The company's ability to obtain Medicare coverage and reimbursement is a potential risk.
• Personalis may opportunistically raise additional capital through various means, which could dilute existing shareholders.

Future Outlook

The company anticipates that its increased revenue and strategic partnerships will enable it to achieve its current and future priorities and milestones, with a potential pathway to cash flow break-even.

Management Comments

• In 2024, we grew annual revenue approximately 15% and executed on our key priorities and milestones, setting us up well for 2025, said Chris Hall, Chief Executive Officer and President.
• We ended the year strongly with the execution of a long-term commercial collaboration with Moderna and a strategic investment of $50 million from Merck, endorsing our technology platform and capabilities to support our partners initiatives, and providing a pathway to cashflow break-even.

Industry Context

The announcement reflects the growing demand for precision oncology and genomic testing, with Personalis positioning itself as a key player through strategic partnerships and technology advancements. The decrease in revenue from Natera highlights the competitive landscape and the need for diversified revenue streams.

Comparison to Industry Standards

• Personalis's 15% revenue growth is a solid performance in the genomics sector, but it is important to compare this to other companies in the space such as Exact Sciences (EXAS) and Guardant Health (GH), which have shown varying growth rates.
• The strategic investment from Merck is a positive sign, similar to other biotech companies that have secured funding from large pharmaceutical firms to validate their technology.
• The decrease in revenue from Natera is a concern, as it highlights the risk of relying on a single customer, similar to other companies that have faced challenges when key partnerships change.
• The increase in molecular test deliveries is a positive trend, but it needs to be compared to the growth rates of other diagnostic testing companies to assess its competitiveness.

Stakeholder Impact

• Shareholders will likely react positively to the full-year revenue growth and strategic investments.
• Employees may be encouraged by the company's progress and future prospects.
• Customers may benefit from the company's continued innovation and partnerships.
• Suppliers may see increased business opportunities with the company's growth.

Next Steps

• The company will continue to execute on its key priorities and milestones.
• Personalis will focus on leveraging its partnerships with Moderna and Merck.
• The company will work towards achieving cash flow break-even.

Key Dates

Keywords

genomics, precision oncology, revenue, molecular tests, cash balance, pharma tests, strategic investment, Moderna, Merck, VA MVP